Calidi Biotherapeutics (CLDI) News Today $0.48 -0.02 (-3.63%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$0.51 +0.03 (+6.67%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Calidi Biotherapeutics (NYSE:CLDI) Shares Down 0.3% - Time to Sell?April 29, 2025 | americanbankingnews.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711April 25, 2025 | globenewswire.comCalidi appoints Eric Poma as CEO, directorApril 24, 2025 | markets.businessinsider.comCalidi announces FDA clearance of IND application for CLD-201April 18, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17, 2025 | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 29, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comIBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | finance.yahoo.comCalidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | theglobeandmail.comCalidi announces ability to deliver transient gene therapy to tumorsMarch 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformMarch 10, 2025 | globenewswire.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 28, 2025 | finanznachrichten.deCalidi commences recruitment for multiple dose CLD-101 trialFebruary 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalFebruary 24, 2025 | globenewswire.comCalidi Biotherapeutics expands stock offering capacityFebruary 5, 2025 | msn.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5January 30, 2025 | markets.businessinsider.comCLDI Stock Plummets to 52-Week Low at $0.6 Amid Market TurbulenceJanuary 30, 2025 | msn.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5January 29, 2025 | globenewswire.comCalidi announces termination of standby equity purchase agreementJanuary 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementJanuary 28, 2025 | globenewswire.comCLDI stock touches 52-week low at $0.73 amid market challengesJanuary 22, 2025 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Prices $4.25 Million Public OfferingJanuary 13, 2025 | theglobeandmail.comCalidi to present new data on systemic virotherapy RTNova platformJanuary 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025January 13, 2025 | markets.businessinsider.comCalidi Biotherapeutics Prices Offering Of 5 Mln Shares At $0.85/Share, Stock FallsJanuary 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics slumps 29%, prices $4.25M stock offeringJanuary 10, 2025 | msn.comCalidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockJanuary 10, 2025 | globenewswire.comCalidi announces common stock offering, no amount givenJanuary 9, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Proposed Public OfferingJanuary 8, 2025 | globenewswire.comAllan Camaisa Sells 10,000 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) StockDecember 19, 2024 | insidertrades.comCalidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment InnovationDecember 13, 2024 | theglobeandmail.comCalidi Biotherapeutics prices $7.5M secondary offeringDecember 12, 2024 | msn.comCalidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer CareDecember 9, 2024 | theglobeandmail.comCalidi Biotherapeutics (NYSE American: CLDI) Showcases RTNova Virotherapy BreakthroughNovember 19, 2024 | theglobeandmail.comCalidi Biotherapeutics Reveals Promising Virotherapy DataNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics: Innovative Cancer Treatment with Promising Clinical Results but Financial ChallengesNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung CancerNovember 18, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common StockNovember 15, 2024 | globenewswire.comCalidi prices 4.4M shares at $1.69 in public offeringNovember 14, 2024 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common StockNovember 14, 2024 | globenewswire.comCalidi Biotherapeutics Surges on 3Q Report, Retreats on Stock-Offer NewsNovember 14, 2024 | marketwatch.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.370.72▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼01▲CLDI Articles Average Week Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BeyondSpring News Today Kronos Bio News Today Precision BioSciences News Today Immix Biopharma News Today OKYO Pharma News Today PepGen News Today Immuneering News Today Karyopharm Therapeutics News Today PMV Pharmaceuticals News Today Avalo Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.